InVivo Therapeutics Appoints Chief Financial Officer

InVivo Therapeutics Holdings Corp. has appointed Christopher McNulty as chief financial officer (CFO), effective March 29. He has taken over for interim CFO Melanie Morel-Ferris, who will remain as the company’s senior director of finance and controller.
 
Prior to being appointed CFO, McNulty served at InVivo as senior vice president of business development and investor relations, where he was responsible for evaluating all partnerships and licensing opportunities. In addition to his responsibilities in business development, McNulty played a key role in the company’s financings, including a follow-on offering and registered direct financing totaling an aggregate value of more than $40 million. Prior to joining InVivo, McNulty served as senior director of business development at Repligen Corporation. At Repligen, he led all aspects of the company’s acquisition of Novozymes Sweden, including financial modeling, diligence, strategy, and negotiation. Previously, he served as director of corporate development at Seventh Sense Biosystems, where he was responsible for corporate strategy, market evaluation, and business development.

McNulty received his bachelor of science and M.Eng. degrees in electrical engineering and computer science from MIT, and his M.B.A. from Harvard Business School.
 
Mark Perrin, CEO and Chairman of the Board, said, “I am very pleased to have Chris as our new CFO. He has been instrumental in our corporate financings and investor relations activities to date. In addition, his background in strategic transactions and corporate strategy will continue to make him a valuable asset in a range of corporate activities. I also wish to acknowledge the excellent work Melanie Morel-Ferris has done at InVivo since joining in mid-2016, including her work as interim CFO. Melanie will remain as an integral part of our finance team as the company’s senior director, finance and controller.”
 
InVivo Therapeutics Holdings Corp. is a biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, Mass.